Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells

We present representative data from three clinical trials with the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) suggesting that CTCs can be used to measure PD effects.

Source: Seminars in Oncology - June 13, 2016 Category: Cancer & Oncology Authors: Lihua Wang, Priya Balasubramanian, Alice P. Chen, Shivaani Kummar, Yvonne A. Evrard, Robert J. Kinders Source Type: research